Effect of Dapagliflozin on Myocardial Microcirculation and Short-Term Prognosis in Non-Diabetic Elderly Patients with ST Segment Elevation Myocardial Infarction Undergoing Emergency Primary Percutaneous Coronary Intervention
Objective:To investigate the effect of dapagliflozin on myocardial microcirculation and short-term prognosis in non-diabetic elderly patients with ST segment elevation myocardial infarction(STEMI)undergoing emergency primary percutaneous coronary intervention(PPCI).Methods:A total of 90 non-diabetic elderly patients with STEMI who underwent PPCI in a hospital from May 2019 to January 2021 were selected and divided into control group and observation group by random number table,with 45 patients in each group.The control group was given conventional treatment,and the observation group was given dapagliflozin tablets in addition to the treatment given in the control group.The cardiac function[left ventricular end-diastolic diameter(LVEDD),left ventricular ejection fraction(LVEF),N-terminal pro-B-type natriuretic peptide(NT-proBNP)],myocardial microcirculation[contrast score index(CSI)],and blood biochemistry parameters[glucose(Glu),uric acid(UA),interleukin-6(IL-6)]were compared between the two groups,and the occurrence of treatment-emergent adverse cardiovascular events was recorded.Results:After treatment,LVEDD and CSI in the observation group were lower than those in the control group(P<0.05).The levels of UA,IL-6 and NT-proBNP in the observation group were lower than those in the control group(P<0.05).There was no statistically significant difference in the total incidence of adverse cardiovascular events between the two groups(P>0.05).Conclusion:For non-diabetic elderly patients with STEMI undergoing PPCI,dapagliflozin provides multiple benefits,while improving myocardial microcirculation,and no adverse cardiovascular events in the short term are increased.
国家科技期刊平台
NSTL
万方数据
